secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265706
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q3 net revenue $1.0M, net loss $59.7M; DURAVYU Phase 3 fully enrolled; $172.5M financing
--------------------------------------------------------------------------------

- Q3 2025 total net revenue fell to $1.0M from $10.5M YoY; net loss widened to $59.7M ($0.85/share) vs $29.4M ($0.54/share).
- Cash, equivalents & securities $204M at Sep 30; Oct public offering added $162M net, extending runway into Q4 2027.
- Phase 3 LUGANO/LUCIA for wet AMD fully enrolled (>900 patients); topline data expected mid-2026, first-to-market target.
- Initiated pivotal Phase 3 DME program (COMO, CAPRI) with FDA non-inferiority pathway; first dosing in Q1 2026.
- Preclinical data shows DURAVYU inhibits IL-6 inflammation plus VEGF, supporting multi-target mechanism in retina.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312525265706/0001193125-25-265706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312525265706/eypt-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer